Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $29.74 in the last session, down -3.19% from day before closing price of $30.72. In other words, the price has decreased by -$3.19 from its previous closing price. On the day, 0.63 million shares were traded. CRNX stock price reached its highest trading level at $31.17 during the session, while it also had its lowest trading level at $29.72.
Ratios:
We take a closer look at CRNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 17.80 and its Current Ratio is at 17.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 12 ’25 when Betz Stephen F. sold 97,483 shares for $32.23 per share. The transaction valued at 3,141,877 led to the insider holds 99,713 shares of the business.
STEPHEN BETZ bought 97,483 shares of CRNX for $3,151,625 on Jun 12 ’25. On Mar 19 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 2,515 shares for $34.20 each. As a result, the insider received 86,021 and left with 72,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2800794112 and an Enterprise Value of 1654370048. For the stock, the TTM Price-to-Sale (P/S) ratio is 2014.96 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 1188.484 whereas that against EBITDA is -3.943.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.28, which has changed by -0.44751996 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -1.94%, while the 200-Day Moving Average is calculated to be -22.21%.
Shares Statistics:
According to the various share statistics, CRNX traded on average about 824.59K shares per day over the past 3-months and 1139470 shares per day over the past 10 days. A total of 94.13M shares are outstanding, with a floating share count of 86.99M. Insiders hold about 7.63% of the company’s shares, while institutions hold 106.66% stake in the company. Shares short for CRNX as of 1753920000 were 13174063 with a Short Ratio of 15.98, compared to 1751241600 on 10821713. Therefore, it implies a Short% of Shares Outstanding of 13174063 and a Short% of Float of 15.909999999999998.
Earnings Estimates
The current assessment of Crinetics Pharmaceuticals Inc (CRNX) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$1.25, with high estimates of -$1.06 and low estimates of -$1.35.
Analysts are recommending an EPS of between -$3.99 and -$4.92 for the fiscal current year, implying an average EPS of -$4.65. EPS for the following year is -$4.78, with 13.0 analysts recommending between -$3.13 and -$5.57.
Revenue Estimates
For the next quarter, 14 analysts are estimating revenue of $3.64M. There is a high estimate of $6.2M for the next quarter, whereas the lowest estimate is $1M.
A total of 15 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.6M, while the lowest revenue estimate was $2.8M, resulting in an average revenue estimate of $5.75M. In the same quarter a year ago, actual revenue was $1.04MBased on 15 analysts’ estimates, the company’s revenue will be $45.64M in the next fiscal year. The high estimate is $108.78M and the low estimate is $25.11M.
